te (45% RR (5/11) above cut- point and 11% RR (5/44) below cut-point). We note that even the response rate in lower PD-LI expressers is in line with Erbitux, the only targeted therapy approved for head and neck. Pembro shows 69% 1-year survival in advanced melanoma, nivo/combo comparisons remain diffic